EiRX and Almac to collaborate on cancer drug R&D
Irish health care company EiRx says it has signed an agreement with Northern Ireland-based genomics specialists Almac Diagnostics which will aim to develop targeted therapies for the treatment of colorectal cancer. The accord is set to receive a contribution of 400,000 euros ($474,748) from the InterTradeIreland INNOVA Collaborative R&D program.
Under the terms of the alliance, EiRx will use its ALIBI platform to model the mechanisms of resistance to apoptosis that occur during the early stages of colorectal cancer. Almac will carry out analysis of changes in gene expression using its microarray expertise to identify likely targets for new drugs. Financial details of the deal were not made public.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze